The FY2025 (Dec) proxy of Ocular Therapeutix names 18 peer companies for pay. Among Ocular Therapeutix and these peers, CEO pay was the highest of 6 and total shareholder return was 5th highest of 6.
1st highest of 6in Ocular Therapeutix and its pay peers, FY2025 (Dec) by CEO pay:
$5.4M$35.9M
5th highest of 6in Ocular Therapeutix and its pay peers, FY2025 (Dec) by total shareholder return:
$15$364
Pay peer group, FY2025 (Dec) proxy
| ImmunityBio | ||
| Travere Therapeutics | ||
| Ardelyx | ||
| Tarsus Pharmaceuticals | ||
| Agios Pharmaceuticals | ||
| Ani Pharmaceuticals | Not disclosed | Not disclosed |
| Apellis Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Aura Biosciences, Inc. | Not disclosed | Not disclosed |
| Day One Biopharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Esperion Therapeutics, Inc. | Not disclosed | Not disclosed |
| Evolus, Inc. | Not disclosed | Not disclosed |
| EyePoint, Inc. | Not disclosed | Not disclosed |
| Geron | Not disclosed | Not disclosed |
| Harrow | Not disclosed | Not disclosed |
| Ligand Pharmaceuticals | Not disclosed | Not disclosed |
| Phathom Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| SpringWorks Therapeutics, Inc. | Not disclosed | Not disclosed |
| Vericel | Not disclosed | Not disclosed |
18 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.